Recent Articles from GlobeNewswire

Chengdu Dongfang Zhenghuo Culture Media Co., Ltd.

New Zscaler ThreatLabz 2026 Ransomware Report finds attackers stole nearly 900 terabytes of data, increasingly targeted employees with privileged roles, and used GenAI to accelerate operations

RESTON, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Regula, a global developer of identity verification solutions, and Bernini.ai, a Latin American provider of AI agents and agent management technology, are partnering to bring document and biometric identity verification into customer-facing AI conversations. Through the integration, AI agents powered by Bernini.AI’s DAFNE platform can invoke Regula’s technology whenever a customer’s identity needs to be established or reconfirmed, from onboarding to existing-account servicing and higher-risk transactions.

NetSfere Federations enables organizations to work, communicate and collaborate with other organizations, while organizational boundaries that are non-negotiable, set by law, regulation, geography or corporate structure, are never compromised, and each organization retains complete control of its data, privacy, governance and records

CHANGZHOU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The 2026 International New Energy Expo opened in Changzhou on September 29, under the theme "Power for an Infinite Future", focusing on six areas - new trends, technologies, products, applications, scenarios and opportunities. The expo showcased Changzhou's strengths in the new energy industry.

Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio.

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public offering price for each pre-funded warrant and accompanying common warrant is $2.899 (equal to the combined public offering price per share of common stock and accompanying common warrant, minus $0.001), for expected gross proceeds to Pyxis Oncology of approximately $110 million, before deducting underwriting discounts, commissions and offering expenses. If all of the common warrants and pre-funded warrants are exercised in full, Pyxis Oncology would receive additional gross proceeds of approximately $172.6 million, before deducting applicable expenses.

CHICAGO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kodiact today announced the launch of its AI‑native platform that brings intelligent simulation to direct materials for the first time. Built initially for food, beverage, and CPG manufacturers but designed for use across all direct‑materials‑driven industries, Kodiact connects every material to its underlying price drivers and every decision to a unified ledger, giving operators the ability to see what will happen next, not just what has already occurred. Manufacturers can buy the same ingredient from the same supplier in the same month and still pay a 16% different price. That striking 16% gap persists largely because 62% of that price difference remains a year later, driven by upstream volatility that traditional category management tools fail to catch.

PARIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics (“Egle”), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases, today announced positive results from its Phase 1 single ascending dose (SAD) study in healthy volunteers of EGL-003, the company’s Treg-selective interleukin-2 (IL-2) agonist being developed for autoimmune diseases, including atopic dermatitis. The data, which include safety, pharmacokinetic and pharmacodynamic findings across all four dose cohorts, are being presented at the 35th Congress of the European Academy of Dermatology and Venereology (EADV), taking place September 30 – October 3, 2026, in Vienna, Austria (presentation titled “EGL-003 First in Human study: An IL-2 Mutein Inducing Potent and Selective Amplification of Treg with Preferential Activation of Effector/Memory Skin Homing Tregs,” Abstract / ePoster AS-3660 / P1719).

Ad hoc announcement pursuant to Art. 53 LR.

SAN MATEO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced rapid progress and new data from across its bsAb development program. New data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, in Vienna, Austria expanding the growing body of evidence that dual inhibition of TNFα and OX40L has the potential to raise the bar in the treatment of Hidradenitis Suppurativa (HS).

WUHU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The iCAUR V series is set to welcome a new member. The All-Way SUV iCAUR V25 will make its official debut on October 19 during the 2026 iCAUR International User Summit in Wuhu, China, appearing alongside the iCAUR V23 and iCAUR V27 for global users and media, further expanding the iCAUR V series lineup.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in York Space Systems, Inc. (“York Space Systems” or the “Company”) (NYSE: YSS) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until October 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against Simply Good Foods Company (“Simply Good” or the “Company”) (NasdaqCM: SMPL), if they purchased or otherwise acquired the Company’s shares between October 24, 2024 and April 8, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

NEW YORK CITY and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in AEVEX Corp. (“Aevex” or the “Company”) (NYSE: AVEX) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until October 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against HDFC Bank Limited (“HDFC” or the “Company”) (NYSE: HDB), if they purchased or otherwise acquired the Company’s securities between July 17, 2023 and May 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

NEW YORK and NEW ORLEANS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Honeywell Aerospace, Inc. (“Honeywell Aerospace” or the “Company”) (NasdaqGS: HONA) of a class action securities lawsuit.

KELLOGG, Idaho and VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX:BNKR | OTCQB:BHLL) announces that it has elected to issue an aggregate of 100,499 shares of common stock of the Company (the “Interest Shares”) in full satisfaction of the interest payable as of September 30, 2026 under certain debt instruments (collectively, the “Interest Payments”), including (i) an aggregate of 28,714 Interest Shares to certain holders of 5.0% Series 1 secured convertible debentures (the “Series 1 Debentures”) for the aggregate interest of US$76,666.67 owing thereunder, and (ii) an aggregate of 71,785 Interest Shares to certain holders of 5.0% Series 2 secured convertible debentures (the “Series 2 Debentures”, together with the Series 1 Debentures and the Series 2 Debentures, the “Debt Instruments”) for the aggregate interest of US$191,666.67 owing thereunder, in connection with advances to the Company. The Series 1 Debentures and Series 2 Debentures mature on March 31, 2028 and March 31, 2029, respectively.

TOKYO and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced the successful completion of Apollo managed funds’ (“Apollo Funds”) acquisition of Nippon Sheet Glass Co., Ltd., a leading global company in architectural, automotive, and solar glass, and the launch of its new management structure, marking the new beginning of its next phase of growth.

New partnership gives XYPN members exclusive savings on one of the wealth management industry's fastest-growing AI platforms

New partnership gives all XYPN members access to one of the Network's most requested planning solutions

If you purchased or acquired Simply Good Foods common stock between October 24, 2024 and April 8, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

New York, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Namib Minerals ("Namib" or "the Company") (Nasdaq: NAMM), today announced that Bulawayo Mining Company (Private) Limited, a wholly owned subsidiary of the Company, has secured a non-dilutive new term loan facility for US$ 6.5 million (the “New Term Loan Facility”) with African Banking Corporation of Zimbabwe Limited (“BancABC”). The New Term Loan Facility is in addition to the Company’s existing term loan and overdraft facilities with BancABC, with all such facilities consolidated into a single facility (the “Facility”). The Facility strengthens the Company's liquidity and working capital position with the funds from the New Term Loan Facility earmarked for utilisation towards Step 3 of the Company’s Development Timelines and Milestones for Redwing Mine previously announced in July 2026 (the “Development Milestones”).

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

EVERETT, Wash., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Coastal Community Bank (the “Bank”, “Coastal”, “our”, “we”) has earned the silver award in the Best Bank category of the Seattle Times' Best in the PNW program. The recognition reflects the relationships at the heart of our work—our customers, community partners, and dedicated employees. Every day, we strive to be more than a place to bank by helping local businesses grow, supporting community initiatives, and investing in the places we call home.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In HDFC Bank (HDB) To Contact Him Directly To Discuss Their Options

MIAMISBURG, Ohio, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Accelevation Holdings Corp. (“Accelevation”) today announced the pricing of its initial public offering of 30,000,000 shares of its Class A common stock at a public offering price of $18.00 per share, including 10,000,000 shares offered by Accelevation and 20,000,000 shares offered by certain selling stockholders affiliated with Olympus Partners. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Cooper Companies, Inc. (“Cooper” or the “Company”) (NASDAQ: COO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ServiceTitan, Inc. (“ServiceTitan” or the “Company”) (NASDAQ: TTAN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jackson Financial Inc. (“Jackson Financial” or the “Company”) (NYSE: JXN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Taboola.com Ltd. (“Taboola” or the “Company”) (NASDAQ: TBLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dun & Bradstreet Holdings, Inc. (“Dun & Bradstreet” or the “Company”) (NYSE: DNB).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

MCLEAN, Va., Sept. 29, 2026 (GLOBE NEWSWIRE) -- HII (NYSE: HII), America’s largest military shipbuilder and the global leader in autonomous seapower, was awarded a contract by the U.S. Navy to build 10 ROMULUS unmanned surface vessels (USVs) for the Medium Unmanned Surface Vessel (MUSV) program. The award marks a major advancement in the U.S. Navy’s transition from experimentation to fleet-scale deployment of trusted, operational autonomy across the maritime domain.

Châtillon, France, September 29, 2026

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Flutter Entertainment plc (“Flutter” or the “Company”) (NYSE: FLUT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of lululemon athletica inc. (“lululemon” or the “Company”) (NASDAQ: LULU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bally’s Corporation (“Bally’s” or the “Company”) (NYSE: BALY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Press release – No. 18 / 2026

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stitch Fix, Inc. (“Stitch Fix” or the “Company”) (NASDAQ: SFIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of America’s Car-Mart, Inc. (“Car-Mart” or the “Company”) (NASDAQ: CRMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Deep Fission, Inc. (“Deep Fission” or the “Company”) (NASDAQ: FISN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rent the Runway, Inc. (“Rent the Runway” or the “Company”) (NASDAQ: RENT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SolarEdge Technologies, Inc. (“SolarEdge” or the “Company”) (NASDAQ: SEDG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kinross Gold Corporation (“Kinross” or the “Company”) (NYSE: KGC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors J.B. Hunt Transport Services, Inc. (“J.B. Hunt” or the “Company”) (NASDAQ: JBHT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of D-Wave Quantum Inc. (“D-Wave” or the “Company”) (NASDAQ: QBTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corning Incorporated (“Corning” or the “Company”) (NYSE: GLW).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. (“Tyra” or the “Company”) (NASDAQ: TYRA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Boeing Company (“Boeing” or the “Company”) (NYSE: BA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP. If you are an investor who believes that you may have incurred a loss regarding your Babcock & Wilcox Enterprises, Inc. securities ("B & W" or the "Company") (NYSE: BW); such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of L3Harris Technologies, Inc. (“L3Harris” or the “Company”) (NYSE: LHX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against York Space Systems, Inc. (“York” or the “Company”) (NYSE: YSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellebrite DI Ltd. (“Cellebrite” or the “Company”) (NASDAQ: CLBT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tigo Energy, Inc. (“Tigo” or the “Company”) (NASDAQ: TYGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Chief Strategy Officer Matthew Nicoletti to Present

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Smartsheet (SMAR) To Contact Him Directly To Discuss Their Options

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.